BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223529
CREATED:20211109T085834Z
LAST-MODIFIED:20211109T121023Z
UID:32029-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement - Drug Development Summit Europe
DESCRIPTION:Decipher Mechanisms of Action\, Understand Clinical Data & Ignite Partnership Opportunities to Accelerate Your Microbiome Research \n \nWhilst emerging phase 3 data is set to ignite investment and uncover the reality of microbiome-based therapeutics\, there remain analytical challenges and translational bottlenecks that the community must come together to overcome\, to redefine biopharmaceutical treatment and diagnostic options. \nThe community is now closer than ever to obtaining an available\, approved and commercial microbiome-based therapeutic. This conference joins scientists\, clinicians\, entrepreneurs and academics\, to help assist this success. Persistent hurdles and ongoing challenges with microbiome drug development mean that real-life discussions and learnings are imperative to moving this exciting field forward. \nFrom understanding the microbiome functionality\, leveraging lessons from pre-clinical and clinical development\, scaling manufacturing processes and regulation hurdles\, our discussion will leave you with a holistic view of the European end-to-end development of microbiome therapeutics. \nThe Microbiome Movement provides the perfect opportunity to actualise the therapeutic promise that the microbiome has provided\, by bringing these challenges to the forefront and tackling them head on over three days of extensive content. With the sharing overall aim to commercialise a microbiome-based product. \nTo know more visit: https://ter.li/rk0suq
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-drug-development-summit-europe/
LOCATION:The Tower Hotel\, St. Katharine's Way\, London\, E1W 1LD\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223529
CREATED:20211118T125316Z
LAST-MODIFIED:20211118T125437Z
UID:32119-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:HFpEF Drug Discovery & Development Summit 2022
DESCRIPTION:Heart failure affects about 6.2 million people in the United States\, with half of the patients having heart failure with preserved ejection fraction (HFpEF) and counting. Yet\, there is no treatment for this form of the disease as HFpEF is a heterogeneous syndrome and\, like other disease areas\, this makes it difficult to develop effective therapeutics that will work for patients in each of the subtypes. \nThe HFpEF Drug Discovery & Development Summit 2022 is the first industry-specific forum exclusively focused on showcasing the latest drug development and translational research in HFpEF and its relationship with metabolic syndromes and co-morbidities\, whilst giving you the pivotal insights you need to kickstart the next generation of clinically defining therapeutics for HFpEF to avoid late-stage clinical trial failures. \nWith 20+ hours of content\, an interactive workshop\, and over 5 hours of networking with key industry leaders from Amgen\, Cardiobiopharma\, AstraZeneca\, NeoProgen\, Eli Lilly\, Bayer\, Novartis\, and more\, this comprehensive forum will completely focus on innovative research and state of the art science in HFpEF and the current challenges and opportunities in the field. \nMake this your 2022 must-attend meeting and network with 80+ senior CSOs\, CEOs\, research scientists\, and academics committed to tackling this form of heart failure and provide a meaningful impact on the lives of over 3.1 million patients suffering from HFpEF worldwide. \nTake a look at the full event guide here.
URL:https://www.pharmajournalist.com/event/hfpef-drug-discovery-development-summit-2022/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223529
CREATED:20211119T092845Z
LAST-MODIFIED:20211119T094834Z
UID:32188-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:TGF-β for Immuno-Oncology Drug Development Summit
DESCRIPTION:It is clear the world of TGF-β contains vast potential and excitement\, in the past year alone we have seen great advances\, clinical setbacks\, and novel insights into the role of TGF-β. \nOver the last 12 months\, we have seen so many highs and lows\, including clinical updates from large pharma such as Novartis\, Oncotelic Therapeutics\, Sanofi. It is also exciting to see emerging biotechs progressing in this area – from Transcenta’s clearance with the FDA for Ph1 anti-PD-L1/TGFb antibody to Lassen Therapeutics uncloaking $31m for their candidate. \nWith the vast volume of candidates moving into the clinic\, it is vital for this community to reconnect at the 2nd TGF-β for Immuno-Oncology Drug Development Summit\, the definitive industry-led meeting to harness the therapeutic potential of this target and supercharge pipeline progression. \nTailored with 31+ senior leaders\, the 2022 meeting will return with a fresh speaker line-up and dedicated 2 tracks content for a comprehensive guide on TGF-β in immuno-oncology. Whether you are new to this field or a seasoned expert\, this meeting will provide you with the must-know takeaways from biology to translational modeling\, from biomarkers to clinical trial design across 3 days. \nWhat’s New? \n\n31+ world-class speakers from Scholar Rock\, Novartis\, Pfizer\, Mestag Therapeutics\, Takeda\, Cue Bio\, Genentech\, and more\n2 Dedicated Tracks of exclusive preclinical and clinical case studies and data for your invaluable lessons learned\nA TGF-β Boot Camp Day to provide a comprehensive guide on harnessing the potential of this complex target\n\nTo know more visit: https://ter.li/nep8yi
URL:https://www.pharmajournalist.com/event/tgf-%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223529
CREATED:20211119T093246Z
LAST-MODIFIED:20211119T094530Z
UID:32193-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:DDR\, ATR & PARP Inhibitors Summit
DESCRIPTION:The 5th Annual PARP\, ATR & DDR Inhibitors Summit is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications. \nThis is the key in-person biopharma conference for any research team developing inhibitors of specific DDR targets\, in either monotherapy or in combination\, to treat predictable\, identifiable\, DDR-defective cancer indications. \nIf you are a research team striving to create best-in-class DDR therapeutics\, this is the specific networking forum that has been curated with you in mind. \nWhat Will We Cover? \n\nDelve into the progress in PARP\, ATR & Wee1 including biomarker understanding with AstraZeneca\, Bayer\, Repare\, Merck KGaA\, Atrin Pharma\, IMPACT Therapeutics\, Onxeo\, FoRx & Zentalis\n\n\nOptimize pre-clinical development through models\, novel methodologies & imaging technologies to revolutionize translation with NCI\, XPose Therapeutics\, Dana-Farber Cancer Institute & Harvard\n\n\nUncover the therapeutic potential & progress in targeting Polθ\, WRN\, CHK1\, DNA-PK\, USP1\, PARG\, PKMYT1 with Artios Pharma\, Harvard\, NERx Bio\, KSQ Therapeutics\, IDEAYA & Repare Therapeutics\n\n\nDiscover the clinical updates on combination\, dosing\, scheduling & future directions for this exploding field with Newcastle University\, MD Anderson\, National Brain Tumor Society\, Yale\, Breakpoint Therapeutics & Harvard\n\n\nNetwork In Person with your peers\, ask your burning questions\, build connections\, and fully immerse yourself in the world of DDR therapeutics.\n\n\nA Virtual Attendance Option\, giving you access to the same premium quality content as the in-person event\, dedicated virtual networking opportunities\, & the ability to engage with our event partners\n\nTo know more visit: https://ter.li/uzjvgi
URL:https://www.pharmajournalist.com/event/ddr-atr-parp-inhibitors-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223529
CREATED:20211122T104255Z
LAST-MODIFIED:20220104T174404Z
UID:32208-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:mRNA- Based Therapeutics Summit Europe
DESCRIPTION:Built with biopharmaceutical industry insights\, this conference will bring together key opinion leaders from Europe and the rest of the world to delve deep into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity\, delivery & efficacy for immuno-oncology\, infectious diseases and beyond. \nWith 20+ pioneering large pharma\, biotech and academic experts who are shaping the landscape of mRNA- based therapeutics for the scientific community world-wide\, hear how they address the major challenges facing the industry. \nKey Highlights: \n\nOptimise the Efficacy\, Cell- & Tissue- Specificity & Translatability of Your mRNA- Based Pipeline\n\n With the limitless opportunity of mRNA- based Therapeutics across different modalities\, consider the challenges of efficacy and improve cell- & tissue- specificity with expert insights from Professor Drew Weissman\, Strand Therapeutics & Chalmers University of Technology  \n\nExplore Applications of mRNA- Based Therapeutics Beyond Infectious Diseases\n\n From immune-oncology to rare and autoimmune diseases\, dive into emerging applications and potential challenges of mRNA- based vaccines and therapeutics beyond infectious diseases with case studies from Moderna\, BioNTech & Ethris  \n\nNavigate New & Emerging Delivery Technologies for mRNA- Based Therapeutics\n\n Take yourself to the forefront of mRNA delivery system development\, from structure through to administration with insights from BioNTech\, Johnson & Johnson & 20Med Therapeutics  \n\nStrategise Your Scalable & Global mRNA-Based Vaccine Development \n\n With the global outreach of mRNA- based vaccines\, scalability is a major hurdle. Hear the latest technological advances and regulatory standards in mRNA- based vaccine and therapeutic landscape from Sanofi\, Ziphius Vaccines & Arcturus Therapeutics  \n\nTune into How Companies are Differentiating Their Pipelines Beyond mRNA- Based Vaccines\n\n With the success of mRNA- based vaccines fulfilling novel technologies and therapies such as mRNA- based protein replacement\, hear from companies like Strand Therapeutics\, Turn Biotechnologies & Orna Therapeutics on the emerging strategies that will enable innovation in the field \nTo know more visit: https://ter.li/og1teo
URL:https://www.pharmajournalist.com/event/mrna-based-therapeutics-summit-europe/
LOCATION:Digital Event – CET
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220126
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223529
CREATED:20211118T130234Z
LAST-MODIFIED:20211118T130317Z
UID:32130-1643155200-1643327999@www.pharmajournalist.com
SUMMARY:5th Antigen-Specific Immune Tolerance Summit
DESCRIPTION:Returning for its fifth year\, the Antigen-Specific Immune Tolerance Summit will lean into the industry’s key challenges of understanding the mechanisms inducing tolerance\, characterizing driver antigens of disease\, monitoring immune response\, and accelerating durable therapies into the clinic. \nThis is your comprehensive guide to define your drug development strategy for 2022 and delve into the therapeutic opportunity held by the next generation of antigen-specific immunotherapies. Expect to be involved in interactive discussions on: \n\nExamining the mechanisms underlying immune tolerance to drive antigen and epitope discovery with insights from the NIH\, Vaccibody\, and Imcyse\nLeveraging immune biomarkers and explore immune tolerance in diabetes with Novo Nordisk\, COUR Pharmaceuticals\, and Diamyd Medical\nExploring the diversity of technologies and platforms for antigen delivery withToleranzia\, Idogen AB\, and AnTolRx\, Inc\nOptimizing clinical durability and efficacy of antigen-specific immunotherapies with insights from WORG Pharmaceuticals\, and Cellerys\n\nUniting 80+ industry experts to discuss cutting-edge content exploring the latest advances in the field of antigen-specific immune tolerance\, this is a conversation not to miss. \nTake a look at the event guide here.
URL:https://www.pharmajournalist.com/event/5th-antigen-specific-immune-tolerance-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220209
DTEND;VALUE=DATE:20220211
DTSTAMP:20260515T223529
CREATED:20211013T105724Z
LAST-MODIFIED:20220114T094327Z
UID:31828-1644364800-1644537599@www.pharmajournalist.com
SUMMARY:SMi’s 13th Annual RNA Therapeutics Conference
DESCRIPTION:SMi Group’s 13th Annual Conference: \nRNA Therapeutics 2022\n9th – 10th February 2022\nVirtual Conference: Online Access Only\nwww.therapeutics-rna.com \nSponsored by: BIA Separations | eTheRNA Immunotherapies | Thermo Fisher Scientific \nBolstering the latest advances and opportunities in RNA-based medicine \nThe RNA therapeutics industry has grown at an exponential rate in recent years\, with an increased spotlight following the industry’s leading role in developing vaccines against COVID-19 in response to the global pandemic. This year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development. \nThe 2022 agenda will explore innovations in novel and targeted delivery\, RNAi innovations and antisense oligonucleotide therapeutics. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of RNA with case studies on the treatment of cardiovascular disease\, neurological diseases\, and oncology.
URL:https://www.pharmajournalist.com/event/smis-13th-annual-rna-therapeutics-conference/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="SMi Group Ltd":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220209
DTEND;VALUE=DATE:20220211
DTSTAMP:20260515T223529
CREATED:20211210T000811Z
LAST-MODIFIED:20220117T123916Z
UID:32418-1644364800-1644537599@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual 3D Cell Culture Conference
DESCRIPTION:SMi’s 5th Annual 3D Cell Culture Conference \nVirtual Conference: Online Access Only \n9-10 February 2022 \nhttp://www.3d-cellculture.com/ \nSponsored by: CELLINK\, CelVivo\, Promega and Newcells BiotechDeveloping Complex\, Translatable and Physiologically-Relevant Cellular Models in vitro \nConference Co-Chairs: Stefan Przyborski\, Professor of Cell Technology\, Durham University and Philip Hewitt\, Global Head of Early Investigative Toxicology\, Merck \n3D Cell Culture is gaining momentum in the pharmaceutical industry on account of the advantages such models pose for in drug discovery\, from improved clinical translation and predictivity\, to patient safety and sustainability. \nSMi’s 3D Cell Culture Conference will explore advances in the application of 3D cell models\, from their employment in drug screening to reduce candidate attrition\, to the latest insights into microphysiological systems\, the regulatory landscape\, and the clinical applications of 3D bioprinting. \nEvent Hashtag: #SMi3DCellCulture \nKey Benefits of Attending: \n\nDiscuss the uses of advanced cell technologies to construct in vitro models of human tissues\nExplore the regulatory sciences surrounding Microphysiological systems\, and their development and adoption for drug safety assessment\nUncover the major benefits of 3D modelling in enhancing clinical translation and predictability\nUtilise 3D cell culture for High Throughput drug discovery and Content screening over traditional 2D methods\n\n\n• Delve into advanced case studies looking into organ models: from organotypic lungs to liver spheroids\n\n WHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist \nAcademia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer
URL:https://www.pharmajournalist.com/event/smis-5th-annual-3d-cell-culture-conference-2022/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220214
DTEND;VALUE=DATE:20220217
DTSTAMP:20260515T223529
CREATED:20211029T081249Z
LAST-MODIFIED:20211029T081249Z
UID:31932-1644796800-1645055999@www.pharmajournalist.com
SUMMARY:4th Bacteriophage Therapy Summit
DESCRIPTION:From Translation to Market-Entry: Advance Formulation\, Clinical Development\, & Commercialization of Phage-Based Therapies at the 4th Bacteriophage Therapy Summit 2022. \nReturning for its 4th year\, the Bacteriophage Therapy Summit remains the only industry-focused forum dedicated to facilitating the discovery\, translation & acceleration of bacteriophage research into targeted therapeutics with clinically significant results. View the full event guide here: https://ter.li/ehl7e1 \n2022 Agenda Overview: \n\nNavigate clinical trial rationale\, distribution effects of formulation on reaching infection sites\, lessons learned from compassionate use trials\, and the regulatory pathway for commercial development with the hottest insights from our 35+ expert speaker faculty\nHear from international organizations including the FDA\, BiomX\, Locus Bioscience\, Felix Bioscience\, Phagomed\, PhagePro\, Cytophage\, Sciphage and unite with the phage community prioritizing human health and diseas\nDiscuss strategies to weaponize phage therapies including lysins\, genetic engineered and combination approaches to create new pathways for the treatment of infectious diseases\, across 3 days of unparalleled\, industry-centered content\nKeep your company’s interest in bacteriophage therapies up-to-date and aligned with the new breakthroughs beyond basic science and establish your pathway to commercialization in 2022 and beyond\n\nSee our full speaker faculty\, all agenda topics\, and our attending audience in our event brochure: https://ter.li/ehl7e1 \nJoin us to develop the next generation of phage therapy products disrupting the medical and healthcare industries for a better tomorrow. Early booking and group discounts are available upon request. Please visit the website for more information on registration fees and discounts. https://ter.li/1szl1y
URL:https://www.pharmajournalist.com/event/4th-bacteriophage-therapy-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220215
DTEND;VALUE=DATE:20220218
DTSTAMP:20260515T223529
CREATED:20211105T123049Z
LAST-MODIFIED:20211105T123049Z
UID:31997-1644883200-1645142399@www.pharmajournalist.com
SUMMARY:2nd Operationalize: Expanded Access Programs Summit
DESCRIPTION:This 2nd Operationalize: Expanded Access Programs summit is here to bring you solutions. \nBy bringing together the world’s leading Expanded Access Programs thinkers\, this exclusive platform will clarify the complex issues through end-to-end Managed Access/Compassionate Use program operationalization. Through open discussion\, sharing best-practice case studies\, and removing hypotheticals: this event provides an unrivaled opportunity to solve your challenges across the entire timeline. \nWhether it’s program set-up\, US and EU regulatory pathways\, product supply\, data collection\, logistics\, ethical considerations\, or internal collaborating – ensure you aren’t repeating past mistakes by hearing global leaders recall their experiences with a shared goal of providing you with pragmatic solutions to solve these complex hurdles. \nFor more information visit: https://ter.li/f41rv0
URL:https://www.pharmajournalist.com/event/2nd-operationalize-expanded-access-programs-summit/
LOCATION:Aloft Boston Seaport District\, 401-403 D St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220221
DTEND;VALUE=DATE:20220224
DTSTAMP:20260515T223529
CREATED:20211202T111335Z
LAST-MODIFIED:20211202T111335Z
UID:32303-1645401600-1645660799@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences Europe
DESCRIPTION:LEAP HR: Life Sciences Europe is your best opportunity to uncover the brand-new HR thinking that will enable you to tackle an ongoing talent shortage\, and create the differentiated people strategies and organisational agendas you need to thrive in a hybrid life sciences operating environment. \n \nStep inside 20+ case studies of how biopharma organisations of all sizes are thriving in new-hybrid working models – and leave with the inspiration you need to transform HR impact in your own organisation.  Look beyond what’s previously not been possible and focus on how HR can transform its strategic impact in this fundamentally new working world that will enable your own organisation to compete more effectively for top life sciences talent. \nFind out more > https://ter.li/tw2ss2
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-europe/
LOCATION:The Pestana Amsterdam Riverside\, Amsteldijk 67\, Amsterdam\, 1074 HZ\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260515T223529
CREATED:20211101T103734Z
LAST-MODIFIED:20211101T103819Z
UID:31980-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
DESCRIPTION:The Only Global RAS Dedicated Conference is Returning in 2022 with the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit!\nYear on year\, we are proud to unite the leading frontiers of the RAS industry to showcase expertise\, technical data and pipeline updates\, all geared toward accelerating the discovery and development of anti-RAS therapies. \nThis February 2022\, the summit returns to shine a spotlight onto pioneering discoveries and innovative strategies to target RAS\, including a focus on success in targeting mutations beyond G12C and efforts to shut down the RAS/MAPK pathway at every turn. \nAs the industry springboards off the significant success of G12C covalent inhibitors against KRAS mutant cancers\, leading experts are now shifting focus toward next-generation anti-RAS drugs\, considering how we can leverage the RAS signaling pathway to treat all RAS mutant cancers\, and overcome the critical escape mechanisms leading to treatment resistance. \nTo know more visit: https://ter.li/8ljo2k
URL:https://www.pharmajournalist.com/event/3rd-ras-mapk-pathway-targeted-drug-discovery-summit/
LOCATION:8:30am – 5pm | Boston\, MA In-Person and Digital Options Available
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260515T223529
CREATED:20211109T113013Z
LAST-MODIFIED:20211109T113013Z
UID:32042-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:Next Generation CAR-TCR Summit
DESCRIPTION:As the CAR-T field continues to explode with new companies\, investment\, and clinical collaborations\, it’s more important than ever to stay ahead of the curve. Stakeholders across oncology are now turning to next generation developments and innovations to create the therapies of tomorrow. \nThat’s why CAR-TCR Europe has evolved into the Next Generation CAR-TCR Summit: your definitive platform focused on the 2.0\, next generation innovations in cell therapies. \nJoin you CAR-TCR community and network with 300+ innovators from large pharma\, biotech\, academia and regulatory boards at the only meeting dedicated to accelerating novel\, new generation cell therapies that are safer\, more effective and have meaningful impact in diseases beyond oncology. \nYou’ll hear insights into novel in-vivo delivery\, innovations in gene\, base & prime editing\, novel discovery platforms\, overcoming the hostile tumour microenvironment\, improving persistence & durability for greater clinical outcomes\, and more! \nKey insights will be shared from Matterhorn Biosciences\, Affini-T Therapeutics\, Kiromic BioPharma\, Antion Biosciences\, Zelluna Immunotherapy\, T-Kinfe Therapeutics\, AffyImmune and many more. Leverage their knowledge to deliver value to your entire cell therapy team. \nWith 3 in-depth streams exploring the hottest Novel Platforms\, Advanced Clinical Development of 3rd\, 4th and 5th generation cell therapies\, and the latest Manufacturing Innovations to revolutionise the production of large-scale cell therapy\, this is the ONLY meeting bringing you the next generation developments and innovations needed to create the therapies of tomorrow. \nWhether you are developing novel constructs\, new clinical trial strategies or innovative manufacturing approaches for large scale production\, this multi-tracked meeting can support your whole team and provide the tools needed to advance your own pipeline towards clinical and commercial success. \nView official event guide now for the full meeting details!
URL:https://www.pharmajournalist.com/event/next-generation-car-tcr-summit/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260515T223529
CREATED:20211129T180236Z
LAST-MODIFIED:20211129T180236Z
UID:32287-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:2nd Mitochondria-Targeted Drug Development Summit
DESCRIPTION:We are happy to announce that the Mitochondria-Targeted Drug Development Summit\, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction\, will be delivered in-person\, for its 2nd edition.\nMitobridge/Astellas\, Minovia Therapeutics\, Abliva\, GenSight Biologics\, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies. \nTo know more visit: https://mitochondria-targets.com/
URL:https://www.pharmajournalist.com/event/2nd-mitochondria-targeted-drug-development-summit/
LOCATION:Hyatt Regency Boston / Cambridge\, 575 Memorial Dr\, Cambridge\, MA\, 02139\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220301
DTEND;VALUE=DATE:20220304
DTSTAMP:20260515T223529
CREATED:20211118T125811Z
LAST-MODIFIED:20211118T125903Z
UID:32125-1646092800-1646351999@www.pharmajournalist.com
SUMMARY:4th Chronic Kidney Disease Drug Development Summit
DESCRIPTION:As SGLT2 inhibitors redefine standard of care\, opportunities to establish efficacy with surrogate endpoints take a step forward\, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting. \nThe 4th Chronic Kidney Disease Drug Development Summit is your only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. Uniting 100+ industry heavyweights including AstraZeneca\, Johnson & Johnson\, Bayer\, Boehringer Ingelheim\, Novartis\, Otsuka\, Novo Nordisk\, and many more\, this is a conversation you cannot afford to miss. \nFrom dissecting pivotal insight into implementing patient stratification to turn the tide on precision medicine\, to the brand-new seminar dedicated to establishing a pathway to clinical success in AKI\, this is the only end-to-end forum presenting scientific advancements as actionable insights. \nWe hope to see you in Boston this March to together discover opportunities to personalize organ-on-a-chip technology and explore advances in stem cell platforms to regenerate kidney tissue. Leave this meeting equipped to guide your strategic decisions for 2022 and implement evolving surrogate endpoints of eGFR slope\, albuminuria\, and real-world evidence into innovative trial design. \nTake a look at the event guide here.
URL:https://www.pharmajournalist.com/event/4th-chronic-kidney-disease-drug-development-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220308
DTEND;VALUE=DATE:20220311
DTSTAMP:20260515T223529
CREATED:20211214T011809Z
LAST-MODIFIED:20211214T011809Z
UID:32510-1646697600-1646956799@www.pharmajournalist.com
SUMMARY:Transcription Factor-Directed Therapies Summit
DESCRIPTION:The FDA’s recent approval of Welireg has sparked reinvigorated confidence in the field of Transcription Factor-therapeutics and as an increasing number of drug candidates are entering preclinical and clinical programs\, this is a vital moment for the field. \nFor the first time\, you can join leaders from BMS\, Scorpion Therapeutics\, Ikena Oncology\, Kronos Bio and Talus Bio at the inaugural Transcription Factor-Directed Therapies Summit\, the first in-person conference on precision molecular oncology uniting experts in proteomics\, genomics\, structural biology\, and translational sciences. \nDedicated to overcoming specific drug development challenges of targeting this ubiquitous and highly complex system with novel TPD based modalities\, this unique discussion forum will equip you with the knowledge to utilize Transcription Factors as biomarkers to better predict disease prognosis and progression. \nDon’t miss your chance to join fellow pioneers of Transcription Factor medicine to overcome the critical roadblocks to success in small molecule inhibitors\, PROTAC-based degraders\, and other therapeutic approaches targeting STAT3\, c-MYC\, FOXP3\, p53\, MITF\, NF-B\, and many more Transcription Factors. \nEnsure your Transcription Factor program reaches full clinical potential by gaining a better understanding of the underpinning biology of the transcription regulation network and how it relates to treating disease\, whilst harnessing the novel discovery and screening technologies that are streamlining drug development and opening the field up to new therapeutics possibilities. Join us to seek out solutions to longstanding obstacles in transcription factor therapy development at all stages\, from bench to bedside. \nTo know more visit: https://bit.ly/3pWWEj8
URL:https://www.pharmajournalist.com/event/transcription-factor-directed-therapies-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220314
DTEND;VALUE=DATE:20220316
DTSTAMP:20260515T223529
CREATED:20211220T170251Z
LAST-MODIFIED:20211220T170251Z
UID:32612-1647216000-1647388799@www.pharmajournalist.com
SUMMARY:SMi’s 3rd Annual AI in Drug Discovery Conference
DESCRIPTION:SMi’s 3rd Annual AI in Drug Discovery Conference \nConference: 14 – 15 March 2022\nLondon\, UK\nWebsite: http://www.ai-indrugdiscovery.com/PJwl \nChaired by Darren Green\, Director of Computational Chemistry\, GSK \nSponsored by: Optibrium \nExploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare \nSMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference\, taking place on the 14th and 15th March 2022 in London\, UK. \nWith the recent pandemic highlighting the need for rapid drug discovery\, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts. \nAI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nAI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating ‘Big Data’ and data scientists within their R&D teams. Although the AI in drug discovery area has grown rapidly over the past few years\, those in the industry acknowledge that there is a long way to go. Collaboration and partnerships are the key to driving this area forward. \nJoin us at SMi’s 3rd annual AI in Drug Discovery conference and explore the latest industry updates in: the selection of targets using AI\, decision making within drug discovery and closing the loop on AI in drug discovery. Don’t miss out on presentations from leaders within the field\, giving insights into the latest industry advances and answering the big questions within AI in Drug Discovery. \nEvent Hashtag: #SMiAIDrugDis \nKey Reasons to Attend: \n\nDiscover the main topics of research within industry\, with talks on decision making\, target selection and closing the loop\nEngage with regulators about the guidance within machine learning and AI in Drug Discovery\nLearn about the new breakthroughs within clinical trials and the treatment of disease\nExplore the latest technologies in deep learning from leaders within the pharmaceutical industry\nDiscuss the impact of big data and how it applies to AI drug discovery within Pharma\n\nWho Should Attend? \nCEOs\, Presidents\, Vice Presidents and Global Heads\, Executive Directors\, Vice President & Global head\, Principal Scientists\, Heads of Business Development\, Directors of Pharma/Biotech firms.
URL:https://www.pharmajournalist.com/event/smis-3rd-annual-ai-in-drug-discovery-conference/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220315
DTEND;VALUE=DATE:20220318
DTSTAMP:20260515T223529
CREATED:20211122T103557Z
LAST-MODIFIED:20211227T114657Z
UID:32201-1647302400-1647561599@www.pharmajournalist.com
SUMMARY:2nd TPD Europe Summit
DESCRIPTION:2021 marked a successful year for the protein degradation field with several candidates entering the clinic. As the European centric targeted protein degradation landscape matures and the number of pre-clinical candidates expected to enter clinical development in the next year grows ever more\, the 2nd TPD Europe Summit returns\, in person\, to highlight key challenges and opportunities ahead! \nBuilt with biopharma in mind\, join us as we take a deep dive into how European leaders of protein degradation are approaching key translational challenges including optimisation of selectivity\, bioavailability and PKPD to ensure the safety\, efficacy and potency of their clinical pipelines in 2022 and beyond! \nBe at the heart of the discussion by joining 180+ Senior Scientists\, Principal Investigators & Heads of Discovery\, Pre-Clinical & Translational Development from Europe and around the globe for two dedicated streams of exciting content over three days to capitalise on this emerging therapeutic class. \nKey Highlights Not to Miss: \n\nHear from Kevin Moreau\, Assoicate Director PROTAC Safety Science\, AstraZeneca as he discusses key PROTAC safety considerations for both oncology and non-oncology indications including how to optimise the safety profile\, and what is acceptable for non-oncology targets\n\n\nDelve into COFFEE (covalent functionalisation followed by E3 electroporation)\, which tests neo-substrate degradation by chemically modified E3 ligase components. Brought to you by Benika Pinch\, Principal Scientist\, Novartis\, she discusses how to assess the cellular activity of E3 ligase components\n\n\nUncover how protein manipulation using peptides can be used to degrade proteins using either the UPS or lysosomal pathways. This exciting approach relocates protein within the cell and modulates their interactions. Hear Max Cynader\, CEO & Co-Founder Primary Peptides discuss in detail!\n\n\nAmine Sadok\, Head of Biology at Monte Rosa Therapeutics will be discussing how they have identified a potent and selective NEK7 molecular glue degrader as a novel CRBN neo-substrate\n\nDigital passes available \nTo know more visit: https://ter.li/j3ytqu
URL:https://www.pharmajournalist.com/event/2nd-tpd-europe-summit/
LOCATION:London\, UK
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220321
DTEND;VALUE=DATE:20220323
DTSTAMP:20260515T223529
CREATED:20211125T120837Z
LAST-MODIFIED:20211125T133706Z
UID:32219-1647820800-1647993599@www.pharmajournalist.com
SUMMARY:SMi Presents the 16th Annual Conference: Parallel Trade 2022
DESCRIPTION:SMi’s 16th Annual Conference\nParallel Trade\n21-22 March\, 2022 | Conference\nhttp://parallel-trade.com/pharmajournalistwl \nNAVIGATING THE CHALLENGES AND LEGAL LANDSCAPES OF PARALLEL TRADE \nSMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe\, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. \nThe 2022 event will be more significant than ever before due to the transition period follow Brexit now also coming to an end. As such\, the UK will no longer be part of the EU free market. This will mean increased medicines prices\, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment\, exhaustion of rights will cease to apply to the UK\, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution. \nThis conference will bring together industry experts to discuss the challenges and drivers of the industry\, including the EU regulatory landscape and the impact of the Brexit and the Pandemic together. The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states. \nBenefits of Attending: \n\nDiscover the impact of Covid-19 on Parallel trade as countries begin to release restrictions. How has the sector been influenced?\nEngage in discussions on the growth within parallel trade over the past year at the only Parallel Trade specific conference within the EU.\nDiscuss the impact on UK parallel trade following Brexit\, through the eyes of regulators\, the pharmaceutical industry and academics\nDevelop further understanding of the rules and regulation changes over the past 12 months\, Parallel Trade\, where are we now?\n\nWho Should Attend: \nVice President/ Heads of/General Managers:\n• International Trade and Relations\n• Supply Chain Development – Brexit\n• Brexit Implementation\n• Market Access\n• Supply Chain Manager\n• Parallel trade reporting\n• Regulatory Affairs\n• IP\n• Purchasing\n• Policy Patent Operations\n• European Affairs\n• Supply and Demand\n• Attorney\n• Distribution \nPlease visit http://parallel-trade.com/pharmajournalistwl for more information\, to download the full agenda\, or to register your place.  If you would like to speak to someone about the event please contact Alia Malick amalick@smi-online.co.uk or call +44 (0)20 7827 6168.
URL:https://www.pharmajournalist.com/event/smi-presents-the-16th-annual-conference-parallel-trade-2022/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="Hanson Wade":MAILTO:rjones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220325
DTSTAMP:20260515T223529
CREATED:20211111T123644Z
LAST-MODIFIED:20211111T123644Z
UID:32053-1647907200-1648166399@www.pharmajournalist.com
SUMMARY:GPCRs - Targeted Drug Discovery Summit
DESCRIPTION:The inaugural GPCRs – Targeted Drug Discovery Summit has been established to tap into new drug discovery opportunities in undrugged and orphaned GPCRs by better understanding the complex signaling GPCR pathway\, leveraging new structural and genetic data as well as\, emerging screening tools and technologies and up and coming modalities. \nDiscover data driven case studies that showcase the challenges\, learnings and takeaways currently being faced by large pharma\, biotech and academia who are innovating their discovery and development approaches to drug a wider spectrum of clinically relevant but poorly characterized or undrugged GPCRs across a broad range of therapeutic areas such as oncology\, age-related diseases and beyond. \nWhether you are looking to harness the power of structural biology tools or emerging technologies\, join fellow directors\, heads and VPs of drug discovery\, structural biology\, and pharmacology at the GPCRs – Targeted Drug Discovery Summit – the most comprehensive and dedicated scientific and networking forum for innovative biopharma and research institutes to seize the therapeutic opportunities of GPCRs. \nTo know more visit: https://ter.li/d9fxmw
URL:https://www.pharmajournalist.com/event/gpcrs-targeted-drug-discovery-summit/
LOCATION:DoubleTree Suites Boston-Cambridge\, 400 Soldiers Field Rd\, Boston\, MA\, 02134\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220325
DTSTAMP:20260515T223529
CREATED:20211214T012807Z
LAST-MODIFIED:20220124T113103Z
UID:32513-1647907200-1648166399@www.pharmajournalist.com
SUMMARY:STING & TLR-Targeting Therapies
DESCRIPTION:The 3rd STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field. \nWith multiple TLR agonists moving into the clinic\, STING agonists exposing new challenges\, multiple approvals on the horizon\, and more novel targets & combinations currently undergoing exciting pre-clinical validation than ever before\, this unique and highly anticipated industry-focused meeting will unite experts in innate immunity to overcome the barriers it faces and accelerate clinical breakthrough. \nReturning in-person to the biopharma hub of Boston\, 30+ expert speakers will take you through case-study led presentations\, juicy panel discussions and live Q&A’s\, all tailored to suit your TLR\, STING & other PRR targeting needs. \nGain connections and insights to plan how to optimize the development of your innate immune agonists into the clinic and overcome obstacles that may impede the delivery of more selective\, better-tolerated medicines to improve survival rates in difficult-to-treat cancers. \nTo know more visit: https://ter.li/z3s9wq
URL:https://www.pharmajournalist.com/event/sting-tlr-targeting-therapies/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220401
DTSTAMP:20260515T223529
CREATED:20211130T161037Z
LAST-MODIFIED:20211130T161037Z
UID:32293-1648512000-1648771199@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Blood Disorders
DESCRIPTION:In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies\, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field\, enabling you to progress your pipeline to address the significant unmet need in this field. \nFocused specifically on hemophilia\, beta-thallasemia and sickle cell-directed gene therapies and gene editing approaches\, this event is an invaluable opportunity to learn the realities of durability challenges\, understand strategies to guarantee safety at every stage of development and get a head-start in understanding the most promising technologies set to revolutionise the field. \nIncorporating insights from translational\, clinical and commercial industry experts\, as well as leading clinicians actively involved in late-stage trials\, this is your opportunity to investigate the realities of managing immunogenicity for systemically administered gene therapies\, establishing less cytotoxic conditioning regimens for ex vivo approaches and prepare for the commercial reality of launching a gene therapy and ensuring there is widespread patient adoption. \nTo know more visit: https://ter.li/u41qa2
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-blood-disorders/
LOCATION:Boston Logan Airport Hotel\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220402
DTSTAMP:20260515T223529
CREATED:20211210T094616Z
LAST-MODIFIED:20211210T094922Z
UID:32479-1648512000-1648857599@www.pharmajournalist.com
SUMMARY:12th World ADC London
DESCRIPTION:12th Annual World ADC London\n29th March – 1st April 2022\nLondon \nThe ADC field is going from strength to strength\, further catalysed in 2021 by the approvals of Zynlonta and Tivdak respectively\, bringing the total number of commercially available ADCs to 11. \nReturning in-person in from 29th March – 1st April\, be part of the 12th Annual World ADC London and reconnect with 400+ of your peers at the forefront of ADC drug development. \nAfter in-depth research with key opinion leaders within the ADC field\, this is your most extensive programme to-date addressing the most pressing challenges facing ADC developers from discovery through to late phase manufacturing. \nTake a look at the brand-new agenda here! \nThe four-streamed\, four-day unrivalled programme with 75+ industry-leading speakers will equip you with the insights and connections to nourish your current pipelines of ADCs\, discover the next generation of non-traditional ADCs\, and confidently define your manufacturing processes. \nRegister now and join the likes of the likes of Daiichi Sankyo\, AstraZeneca\, ADC Therapeutics\, Seagen and many more to work collaboratively to overcome the distinct challenges ADC drug development holds and maximise the therapeutic window of ADCs.
URL:https://www.pharmajournalist.com/event/12th-world-adc-london/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220401
DTSTAMP:20260515T223529
CREATED:20220107T124627Z
LAST-MODIFIED:20220107T124627Z
UID:32748-1648512000-1648771199@www.pharmajournalist.com
SUMMARY:Next Generation Kinase Inhibitors Summit
DESCRIPTION:Celebrating 20 years of FDA approval and high efficacy profiles\, kinase inhibitors have changed the face of oncology treatment. However\, increasing resistance and safety issues limit the success of existing kinase inhibitor classes. \nThe inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs which are able to show efficacious and durable clinical response in oncology and beyond. \nBoasting 20+ speakers\, 1 deep-dive workshop and over 3 days of unrivalled content spanning discovery\, R&D and clinical development\, this event is a unique opportunity for your team to identify and target the undruggable\, elevate drug design for improved target selectivity\, overcome the blood brain barrier and rationalize combinations for more durable responses. \nCollaborate with 80+ senior drug developers in March to achieve the next generation of these kinase inhibitor therapies with optimized specificity\, maximal durability to deliver the best clinical outcomes. \nTo know more visit: https://kinase-inhibitors-summit.com/
URL:https://www.pharmajournalist.com/event/next-generation-kinase-inhibitors-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220330
DTEND;VALUE=DATE:20220402
DTSTAMP:20260515T223529
CREATED:20220211T093912Z
LAST-MODIFIED:20220211T094005Z
UID:33197-1648598400-1648857599@www.pharmajournalist.com
SUMMARY:7th Innate Killer Summit 2022
DESCRIPTION:2021 was a game-changing year for the NK cell community. Positive clinical results have forced the field to wake up to the potential of these pioneering approaches. \nSupporting the field since its’ infancy\, the Innate Killer Summit returns for its 7th year as the leading\, industry-defining forum dedicated to advancing the field to achieve clinical success. \nSpanning the current drug development landscape\, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing\, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies. \nGet your copy of the 2022 agenda here. \nJoin over 200 experts to characterize and contrast cell sources\, supercharge combinations\, optimize CMC workflows\, examine expansion protocols for high-quality products at scale\, and move the field towards persistent\, scalable\, and cost-effective innate immune cell therapies. \nPromising unpublished data\, interactive discussion\, and engaging networking opportunities join this exclusive summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.
URL:https://www.pharmajournalist.com/event/7th-innate-killer-summit-2022/
LOCATION:Sheraton San Diego Hotel & Marina\, 1380 Harbor Island Drive\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220404
DTEND;VALUE=DATE:20220408
DTSTAMP:20260515T223529
CREATED:20211109T090819Z
LAST-MODIFIED:20211109T090819Z
UID:32034-1649030400-1649375999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Muscular Disorders Summit
DESCRIPTION:Mitigating Toxicity & Revolutionizing Muscle Targeting \nThe 2nd Gene Therapy for Muscular Disorders Summit will be returning as an in-person event to Boston in April 2022\, to help gene therapy developers targeting muscular disorders to overcome safety and toxicity \nchallenges and effectively translate their programs into the clinic. \nHighlighting AAV and gene editing challenges for Duchenne’s (DMD)\, Limb-Girdle (LGMD)\, Pompe Disease\, X-Linked Myotubular Myopathy and other muscular disorders\, this industry-focused 4-day event will cover:  \n\nOvercoming immunogenicity challenges and mitigate toxicity with high doses\nOptimizing vector and promoter choice and design for more efficient delivery tomuscle targets\nDefining clinically meaningful muscular endpoints to successfully develop and safely deliver the optimal dose to their muscular targets\n\nJoin over 150 fellow industry experts to learn\, share and benchmark yourselves against your competitors\, and overcome the toxicity and dosage challenges hindering the progress of your gene therapy targeting the muscle. \nTo know more visit: https://ter.li/tbbaua
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-muscular-disorders-summit/
LOCATION:Hanson Wade\, Hyatt Regency Boston Downtown\, 1 Ave de Lafayette\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220405
DTEND;VALUE=DATE:20220408
DTSTAMP:20260515T223529
CREATED:20220110T223347Z
LAST-MODIFIED:20220111T091913Z
UID:32756-1649116800-1649375999@www.pharmajournalist.com
SUMMARY:Wet AMD & DME Drug Development Summit
DESCRIPTION:Accelerating the Development of Novel Anti-VEGF\, VEGF-independent Therapies & Drug Delivery Options To Reduce Clinical Burden\, Widen Therapeutic Index & Treatment Options for Non-responders \nThe second edition of the industry-led Wet AMD & DME Drug Development Summit will give comprehensive insight into the current and emerging angiogenesis-\, inflammatory-directed and anti-fibrotic drug development programmes for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD)\, diabetic retinopathy (DR) and diabetic macular edema (DME). \nThe 2022 Summit will include interactive presentations and panel discussions\, covering challenging questions for the whole research community such as: \n\nWhat are the future directions for anti-VEGF therapy to increase patient response rates\, prolong treatment durability and reduce clinical burden?\nWhere is the clinical success for targeting VEGF-independent pathways in this multifactorial disease?\nWhat interventions beyond anti-VEGF give treatment options for refractory or not optimally treated patients?\nHow are drug developers using various drug delivery methods – topical\, intravitreal\, suprachoroidal\, port delivery – to expand the therapeutic window?\nHow has optical coherence tomography (OCT) imaging\, including at-home diagnostic testing\, and artificial intelligence-enabled programming personalized wet AMD and DME treatment and supported clinical trials?\n\nAs the only industry-led forum solely dedicated to finding long-lasting therapeutic interventions for wet AMD and DME\, attendees will have the opportunity to review the multiple pathological mechanisms being actively targeted\, identify the latest clinical data from anti-VEGF suppression (antibody fragments\, delivery systems\, bispecific antibodies\, gene therapy)\, combinational approaches\, non- VEGF pathways (integrin and TKI’s) and VEGF-independent (such as targeting plasma kallikrein) therapies. \nMeet the leading ophthalmology drug developers from big pharma\, biotech and academia searching for treatment breakthroughs and actively gathering clinical evidence to demonstrate a favourable benefit/risk ratio for future products to regulators\, clinicians and payers. \nJoin us next April to hear their latest clinical development programs and identify future portfolio strategies for your organisation. \nTo know more visit: https://ter.li/m98rr7
URL:https://www.pharmajournalist.com/event/wet-amd-dme-drug-development-summit/
LOCATION:Embassy Suites by Hilton Boston Logan Airport\, 207 Porter St.\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220407
DTEND;VALUE=DATE:20220408
DTSTAMP:20260515T223529
CREATED:20211208T111909Z
LAST-MODIFIED:20220309T194319Z
UID:32412-1649289600-1649375999@www.pharmajournalist.com
SUMMARY:Purify’22
DESCRIPTION:PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nThe maiden PURIFY’19 edition was a huge hit amongst fellow chromatographers\, steered by our esteemed advisory board. \nPURIFY’19 was attended by 113 delegates across 19 cities\, spread across 51 corporates with 14 speakers and 6 display zones! \nSo\, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more\, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related. \nDownload Brochure
URL:https://www.pharmajournalist.com/event/purify22/
LOCATION:ITC Kohenur\,Hyderabad
ORGANIZER;CN="Custage Marketing Solutions LP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220412
DTEND;VALUE=DATE:20220415
DTSTAMP:20260515T223529
CREATED:20220114T093101Z
LAST-MODIFIED:20220114T093101Z
UID:32768-1649721600-1649980799@www.pharmajournalist.com
SUMMARY:LNP Formulation & Process Development Summit
DESCRIPTION:Embrace Technology Innovations to Optimize LNP Formulation\, Alternative LNP Raw Materials\, Process Control to Achieve Seamless Scale-Up\, Compliance & Cost Effectiveness  \nThe inaugural LNP Formulation & Process Development Summit is the industry’s first forum dedicated to bringing together drug developers within the LNP field to share the latest scientific breakthroughs on formulation and process development. Across 3 days\, you will address challenges and seek solutions to help you optimize your formulation to enhance stability\, efficacy\, and better characterization for drug product quality. This is your chance to explore the use of alternative polymer lipids to maximize scalability and moving towards cGMP manufacturing for pipeline progression. \nThe global nanopharmaceutical drugs market\, catalyzed by the success of Pfizer/BioNTech and Moderna’s mRNA vaccines\, is poised to reach US$82.7 billion by 2027. The demand of novel LNP to support the delivery of oligonucleotide and nucleic acid-based therapies is growing at an exponential rate. With the overwhelming possibilities of lipid nanoparticles\, there are key questions on formulation\, process development and scalability that still need to be answered. There has been no better time to join forces and help accelerate the development of truly remedial LNP therapeutics. \nTo know more visit: https://ter.li/8hrml3
URL:https://www.pharmajournalist.com/event/lnp-formulation-process-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220419
DTEND;VALUE=DATE:20220422
DTSTAMP:20260515T223529
CREATED:20211206T123933Z
LAST-MODIFIED:20211206T123933Z
UID:32385-1650326400-1650585599@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy Medical Affairs Summit
DESCRIPTION:Transforming Traditional Medical Affairs \nOptimize Medical Affairs Proactive Engagements and Education Initiatives to Successfully Launch the Next Generation of Gene Therapy Products  \nThe 2nd Annual Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role Medical Affairs plays in delivering gene therapies to patients. This is your opportunity to take inspiration from Medical Affairs leaders of the gene therapy world and learn how traditional Medical Affairs approaches are being transformed to meet the unique challenges associated with gene therapy drug development. \nGain actionable insights from first-to-market pioneers\, who will share how to engage effectively with internal clinical\, commercial and regulatory teams as well as external HCPs\, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex\, high priced Gene Therapy products. \nThe summit will provide a dedicated platform that discusses the role and value of Medical Affairs across each of the phases of the gene therapy development cycle. We will delve into the unique challenges encountered when working with gene therapies\, from adapting to the clinical realities of the rare disease space\, to handling long-term follow up and post-launch regulatory scrutiny\, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before. \nTo know more visit: https://ter.li/xciowp
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-medical-affairs-summit/
LOCATION:Westin Boston Seaport Hotel\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR